- US$3.121M Revenues for Q2, 2023 compared to US$415,000 for Q2 2022, representing an increase of 652%
- US$2.656M Gross Profit for Q2, 2023 compared to USD 214,000 for Q2 2022, representing an increase of approximately 1,141%
HERZLIYA, Israel and CALGARY, AB, Aug. 25, 2023 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary intellectual property portfolio, is pleased to announce its financial results for the three and six months period ended June 30, 2023.
“We are thrilled with the significant growth we achieved in the second quarter,” says Iris Bincovich, CEO of Innocan. “Our strategic focus on integrating cannabinoids with existing proven drugs alongside the robust sales from our subsidiary, B.I. Sky Global Ltd., have significantly contributed to this tremendous increase in both revenue and gross profit. We remain committed to our vision and are optimistic about the future.”
Financial highlights for the second quarter of 2023:
- Revenue: The Company posted US$3.121M in revenue for the three months ended June 30, 2023, marking an increase of US$2.706M compared to the three months ended June 30, 2022. This surge in revenue is primarily attributable to the robust sales performance of Innocan’s subsidiary, B.I. Sky Global Ltd.
- Gross Profit: For the three months ended June 30, 2023, the Company reported a gross profit of US$2.656M, compared to US$214,000 for the three months ended June 30, 2022, representing an increase of US$2.442M.
- Cash Balance: As of June 30, 2023, the Company’s cash balance was US$3.373M.
For a comprehensive understanding of Innocan’s consolidated financial statements and related management’s discussion and analysis for the three and six months period ended June 30, 2023, please visit the Company’s profile at www.sedar.com.
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Chronic Pain Management and Epilepsy and Pain Management. (ii) CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti- inflammatory properties targeting the Central Nervous System (CNS). In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
For further information, please contact:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
SOURCE Innocan Pharma Corporation
Originally published at https://www.prnewswire.com/news-releases/innocan-pharma-reports-q2-2023-results-including-us2-706m-increase-in-revenues-compared-to-q2–2022–301910088.html
Images courtesy of https://pixabay.com